progression-free interval remains short and median survival is only 6 months. It would be helpful to identify those patients unlikely to respond to alkylating agents to spare them potentially toxic therapy and allow them to be considered for altemative approaches to treatment.
The Cancer Research Campaign (CRC) has identified a new alkylating agent. temozolomide (Newlands et al. 1997) . which has actis ity against melanoma comparable to that of dacarbazine (Bleehen et al. 1995) . The agent's mechanism of action depends upon the methylation of guanine bases in DNA at the 06 position (Margison and O'Connor. 1990 ). Unrepaired. the lesion can result in chain termination. or initiate ineffective cycles of mismatch repair leading to strand-break formation (Karran and Bignami. 1992 : Griffin et al. 1994 : Voigt and Topal. 1995 . However. the 06-methyl adduct can be removed by the protein 06-methylguanine-DNA methyltransferase (MGMT) in a stoichiometric autoinactivating reaction. There is evidence that MGMT expression is a major determinant of cellular susceptibility to methylating agent chemotherapy: tumour cell lines or xenografts with high levels of protein expression are more resistant to temozolomide and related agents than those which are deficient in MGMT (Yarosh et al. pies in relation to MGMT expression have been less widely studied. Recently. an inverse correlation between clinical response and tumour cell MGMT concentration has been reported in leukaemia patients treated with dacarbazine (Franchi et al. 1992) . and glioma patients treated with a chloroethylnitrosourea (Yanagisawa et al. 1996) . However. in both studies numbers were small. and the distinction between high and low MGMT levels of expression was made retrospectively.
We have examined prospectively the relationship between tumour MGMT concentration. measured in biopsies of cutaneous melanoma or lymph node metastases. and response to treatment with temozolomide in patients with advanced malignant melanoma. Comparison between pretreatment MGMT levels in peripheral blood mononuclear cells and tumour biopsies has also been made in a subset of patients.
MATERIALS AND METHODS Patient selection, treatment and evaluation
Patients with progressive advanced malignant melanoma were eligible for the study. The inclusion criteria were a lesion accessible for biopsy. measurable disease and adequate organ function. A WHO performance status of 3 or less was required. and previous chemotherapy and/or radiotherapy were permitted provided that 4 weeks had elapsed from the last treatment and any toxicity had resolved. Sixty-one patients were registered for the trial at four centres between July 1994 and September 1996. of whom three Table 3 and Figure 1 . There was no significant difference in pretreatment MGMT levels between those who responded to temozolomide and those who did not (P = 0.95: Mann-Whitney test). MGMT levels did not correlate w-ith an individual's time to progression nor overall survival. In ten patients. there was no linear (r = 0.045. P = NS) or rank (r = 0.097. P = 0.40) relationship bettween pretreatment peripheral blood mononuclear cell and tumour biopsy MGMT levels.
DISCUSSION
The overall response rate of 14%7c observed in the present study is lower than that seen in the earlier CRC phase II study of temozolomide in advanced malignant melanoma (Bleehen et al. 1995 ).
However. patients in the earlier study were chemotherapy naive and had a better median performance status at the start of temozolomide therapy. and only one patient had CNS disease (compared with eight in this study). No patient in the current trial who had received previous systemic chemotherapy responded to temozolomide. The majority of the regimens given before temozolomide included dacarbazine. which shares the active intermediate 5-( 3-methyl-1 -triazenvl )imidazole4-carboxamide with temozolomide. so that cross-resistance is not unexpected. However. there was no difference in the mean MGMT levels of patients who had received prior chemotherapy and those who had not (data not shown). The toxicities seen in this study are similar to those in the previous melanoma trial and other phase II studies (Bleehen et al. 1995 : Bower et al. 1997 (Branch et al. 1993 : Kat et al. 1993 . and it has recently been suggested that this deficiency overrides MGMT in conferrinc resistance to temozolomide (Liu et al. 1996 : Wedge et al. 1996 . Results should soon be available from clinical trials w-ith 
